<DOC>
	<DOCNO>NCT01140204</DOCNO>
	<brief_summary>This randomize , placebo-controlled , multi-centre study , double-blind within dose level , four ascend dose level test tolerability safety iopromide-paclitaxel patient de novo lesion coronary artery . Thirty-two patient include trial , divide four treatment group . A total four concentration level paclitaxel-iopromide concentration investigate . In treatment group , six patient receive iopromide-paclitaxel two patient placebo ( iopromide without paclitaxel ) . In patient , dos adjust individually need .</brief_summary>
	<brief_title>Short-Term Exposure Lipophilic Anti-proliferative Drugs Delivered Angiographic Contrast Media</brief_title>
	<detailed_description>Background : Non-stent-based immediate release formulation paclitaxel show reduce in-stent restenosis animal experiment initial clinical trial . Paclitaxel dissolve angiographic contrast agent iopromide well tolerate inhibit neointimal proliferation dose-dependent manner injection porcine coronary artery . Methods : As first step enter clinical development , phase I trial perform use 4 ascend paclitaxel dose/concentration level : sample 100 ml contrast agent contain 10 , 50 , 100 200 μM paclitaxel randomly administer 6 adult patient assign bare metal stent implantation single de novo coronary artery lesion , 8 patient treat plain contrast medium serve control . Safety variables tolerability well angiographic parameter assess .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>male postmenopausal female patient age 18 year old clinical evidence stable unstable angina , positive functional test stentable de novo lesion native coronary artery diameter stenosis &gt; 70 % ( visual estimate ) , lesion length &lt; 25 mm , vessel diameter ≥ 2.5 mm . acute myocardial infarction leave ventricular ejection fraction &lt; 30 % aortoostial lesion unprotected leave main lesion bypass graft clear angiographic calcification target lesion visible thrombus proximal lesion chronic total occlusion platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 WBC &lt; 3,000 cells/mm3 know hypersensitivity contraindication aspirin , heparin , clopidogrel , abciximab , paclitaxel , stainless steel sensitivity contrast medium amenable adequate premedication medical illness ( i.e . cancer , liver disease congestive heart failure ) associate life expectancy less two year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stent</keyword>
	<keyword>contrast medium</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>stent implantation</keyword>
</DOC>